Quantitation of escitalopram and its metabolites by liquid chromatography-tandem mass spectrometry in psychiatric patients: New metabolic ratio establishment

被引:5
作者
Canbolat, Fadime [1 ]
Erinc, Dilek Meltem Tasdemir [2 ]
Evrensel, Alper [2 ]
Aydin, Ahmet [3 ]
Tarhan, Kasif Nevzat [2 ]
机构
[1] Uskudar Univ, NP Brain Hosp, Clin Pharmacogenet Lab, Istanbul, Turkey
[2] Uskudar Univ, NP Brain Hosp, Istanbul, Turkey
[3] Yeditepe Univ, Fac Pharm, Dept Toxicol, Istanbul, Turkey
关键词
escitalopram; LC-MS/MS; therapeutic drug monitoring; validated method; PLASMA-LEVELS; DRUG; CITALOPRAM; LC; PHARMACOKINETICS; ANTIDEPRESSANTS; BLOOD;
D O I
10.1111/bcpt.13133
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Therapeutic drug monitoring (TDM) is used to determine the concentration of drug in plasma/serum to adjust the dose of the therapeutic drug. Selective and sensitive analytical methods are used to determine drug and metabolite levels for the successful application of TDM. The aim of the study was to develop and validate using LC-MS/MS to analyse quantitative assay of escitalopram (S-CT) and metabolites in human plasma samples. In order to provide a convenient and safe treatment dose, it was aimed to determine the levels of S-CT and its metabolites in the patients' plasma. A new method with short sample preparation and analysis time was developed and validated using LC-MS/MS to analyse quantitative assay of S-CT and its metabolites in plasma. Also, plasma samples of 30 patients using 20 mg S-CT between the ages of 18 and 65 years were analysed by the validated method. The mean values of S-CT, demethyl escitalopram and didemethyl escitalopram in plasma of patients were 27.59, 85.52 and 44.30 ng/mL, respectively. At the end of the analysis, the metabolic ratio of S-CT and metabolites was calculated. It is considered that the method for the quantitative analysis of S-CT and its metabolites in human plasma samples may contribute to the literature on account of its sensitive and easy application. Additionally, the use of our data by physicians will contribute to the effective drug treatment for their patients who take S-CT.
引用
收藏
页码:285 / 297
页数:13
相关论文
共 37 条
[11]  
EMA, 2011, GUIDELINE BIOANALYTI, P1
[12]   Escitalopram plasma levels and antidepressant response [J].
Florio, Vincenzo ;
Porcelli, Stefano ;
Saria, Alois ;
Serretti, Alessandro ;
Conca, Andreas .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (09) :940-944
[13]   AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 [J].
Hiemke, C. ;
Baumann, P. ;
Bergemann, N. ;
Conca, A. ;
Dietmaier, O. ;
Egberts, K. ;
Fric, M. ;
Gerlach, M. ;
Greiner, C. ;
Gruender, G. ;
Haen, E. ;
Havemann-Reinecke, U. ;
Sirot, E. Jaquenoud ;
Kirchherr, H. ;
Laux, G. ;
Lutz, U. C. ;
Messer, T. ;
Mueller, M. J. ;
Pfuhlmann, B. ;
Rambeck, B. ;
Riederer, P. ;
Schoppek, B. ;
Stingl, J. ;
Uhr, M. ;
Ulrich, S. ;
Waschgler, R. ;
Zernig, G. .
PHARMACOPSYCHIATRY, 2011, 44 (06) :195-235
[14]   Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations [J].
Ji, Yuan ;
Schaid, Daniel J. ;
Desta, Zeruesenay ;
Kubo, Michiaki ;
Batzler, Anthony J. ;
Snyder, Karen ;
Mushiroda, Taisei ;
Kamatani, Naoyuki ;
Ogburn, Evan ;
Hall-Flavin, Daniel ;
Flockhart, David ;
Nakamura, Yusuke ;
Mrazek, David A. ;
Weinshilboum, Richard M. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (02) :373-383
[15]   Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure [J].
Jin, Yuyan ;
Pollock, Bruce G. ;
Frank, Ellen ;
Cassano, Giovanni B. ;
Rucci, Paola ;
Mueller, Daniel J. ;
Kennedy, James L. ;
Forgione, Rocco Nicola ;
Kirshner, Margaret ;
Kepple, Gail ;
Fagiolini, Andrea ;
Kupfer, David J. ;
Bies, Robert R. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (01) :62-72
[17]  
Kushnir MM, 1999, J ANAL TOXICOL, V23, P1
[18]   Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients [J].
Lima, CAD ;
Baumann, P ;
Brawand-Amey, M ;
Brogli, C ;
Jacquet, S ;
Cochard, N ;
Powell-Golay, K ;
Eap, CB .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2005, 29 (06) :950-954
[19]   Escitalopram - A review of its use in the management of major depressive disorder [J].
Murdoch, D ;
Keam, SJ .
DRUGS, 2005, 65 (16) :2379-2404
[20]   In vivo investigation of escitalopram's allosteric site on the serotonin transporter [J].
Murray, Karen E. ;
Ressler, Kerry J. ;
Owens, Michael J. .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2016, 141 :50-57